- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03647462
Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients (COPD Readmit)
The Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Chronic Obstructive Pulmonary Disease Patients: the COPD Readmit Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Our investigators propose a randomized clinical trial to test hospitalized patients (due to chronic obstructive pulmonary disease, COPD) for obstructive sleep apnea, then randomizing the patients with OSA into CPAP versus usual care. This study is designed to target a high risk population (hospitalized patients) and early initiation of therapy. Our investigators intend to enroll all consenting participants hospitalized with a primary COPD diagnosis. Our study is unique and the answer to its question - whether early diagnosis of OSA and initiation of and adherence to CPAP therapy in hospitalized COPD patients will reduce 30-day readmission rates - is unknown. The objective is twofold: to improve quality of care and decrease preventable hospitalizations through early diagnosis and implementation of this early diagnosis and intervention model for this subset of patients may slow progression of COPD, offset a large public health and financial burden, and improve overall outcomes.
Our investigators believe that our study, which involves human subjects, is in accordance with general ethical principles. It should be noted that the diagnosis and subsequent treatment of OSA during hospitalization is not part of routine practice, and that the control group truly would follow "usual care". Moreover, patients who are deemed very sick (as outlined in the exclusion criteria) will be excluded from the study. Finally half of enrolled participants will receive early CPAP therapy which may potentially benefit those patients beyond what is currently "usual care".
Study Design
Our study is a single-center, randomized control trial designed to evaluate the impact of early diagnosis and treatment of obstructive sleep apnea (OSA) in hospitalized chronic obstructive pulmonary disease (COPD) patients on hospital readmission, symptoms, and healthcare utilization. Consecutive patients who meet inclusion criteria hospitalized with a primary diagnosis of COPD will be asked to participate in the study. Patients who agree and sign consent will undergo a portable sleep study to diagnose OSA-predominant sleep disordered breathing. Patients will also complete a questionnaire packet consisting of the following standardized questionnaires: sleep history questionnaire, Epworth Sleepiness Scale (ESS), Patient Recorded Outcome Measurement Information System (PROMIS), Chronic Obstructive Pulmonary Disease Assessment Tool (CAT), and STOP-BANG questionnaire. Each patient who meets inclusion criteria and consents to the study will undergo an inpatient portable sleep study (ApneaLink, Resmed Corp). This is a Type III study which is an unattended study that measures nasal pressure, respiratory effort, oxygen saturation, and body position. A study investigator will apply the portable device, and a board-certified sleep medicine physician (co-investigators) will interpret these studies. The study will be performed while the patient is on room air (not on oxygen), thus the study may not be applied on the first hospitalized night (if oxygen therapy is required) but delayed until the patient is appropriate to be off oxygen.
A diagnosis of OSA will be made if the apnea-hypopnea index with 4% oxygen desaturation is greater than 5 (AHI4%≥5) with at least 50% of events consistent with obstructive rather than central physiology. Study participants with OSA will then be randomized into one of two pathways: Intervention Pathway and Usual Care Pathway.
Intervention Pathway Patients will receive CPAP therapy in the hospital followed by home CPAP therapy. A sleep center respiratory therapy/sleep technologist case manager will perform a bedside mask fit, CPAP education, and set up their outpatient follow-up appointments with the sleep center. Their home CPAP therapy will be a loaner from the sleep medicine department that includes wireless connectivity so that adherence data is available to the investigators throughout the duration of the study. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (email or text based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
The patients will receive CPAP in addition to the contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete the aforementioned questionnaire packet (with the exception of the STOP BANG questionnaire). Patients will also be asked to follow up within 30 days after discharge for assessment of CPAP use and asked to complete the aforementioned questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms. During the 1 month follow-up appointment, the sleep center will troubleshoot CPAP use when appropriate; otherwise, requests for additional troubleshooting will be at the discretion of the patient (as is currently our usual care).
Usual Care Pathway Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete the aforementioned questionnaire packet (with the exception of the STOP BANG questionnaire). The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 30 days after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Fontana, California, United States, 92335
- Sleep Center; San Bernardino County Medical Center, Kaiser Permanente
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Kaiser Permanente member
- Males or females, any race, and age 18 and older
- OSA-predominant (AHI at or above 5) sleep disordered breathing
- Primary diagnosis upon admission of chronic obstructive pulmonary disease
- Appropriate to perform portable sleep study while on room air (no oxygen)
- Patients who are able and willing to give informed consent
Exclusion Criteria:
- Use of CPAP within 6 months of enrollment
- Patients with CSA-predominant sleep disordered breathing
- Patients who are "sleepy": ESS at or above 11
- Commercial driver's license or other occupational hazards (operating heavy machinery)
- Non-English speaking (validated questionnaires are currently limited to English)
- Patients with chronic respiratory failure requiring oxygen therapy or non-invasive ventilation.
- Patients requiring tracheostomy
- Pregnant patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CPAP Intervention Pathway
Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care. The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms. |
CPAP is an FDA approved therapy machine for patients diagnosed with OSA.
CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep.
CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD.
Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e.
mortality).
Other Names:
|
No Intervention: Usual Care Pathway
Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study.
They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet.
The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study.
Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes.
Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital readmission and mortality rates
Time Frame: 30 days
|
Number of occasions patient has been admitted to the hospital and number of patients who have died
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinic and urgent care visits
Time Frame: 30 days
|
Appointments with any medical providers (sleep, cardiac, primary) at a clinic or urgent care facility
|
30 days
|
Off work orders
Time Frame: 30 days
|
Note from provider ordering/requesting patient to be dismissed from work for medical reasons (sick, injured, etc.)
|
30 days
|
Epworth Sleepiness Scale (ESS)
Time Frame: 30 days
|
Epworth Sleepiness Scale measures degree of sleepiness.
8 scenarios are described and the responder indicates their likelihood of dozing unintentionally (range 0-3).
A total of the scores are added (range 0-24) and typically scores of at least 11 indicate excessive sleepiness.
|
30 days
|
Comparing inpatient portable monitor versus 30-day follow up portable monitor results in usual care group
Time Frame: 30 days
|
Evaluating the change of sleep diagnostic test results from the hospital to 1-month after being discharged (only for patients enrolled in the Usual Care pathway)
|
30 days
|
STOP BANG
Time Frame: 30 days
|
Snoring, tiredness, observed apnea, blood pressure, body mass index, age, neck circumference, and gender (STOP BANG) is the name of a OSA screening questionnaire.
Questionnaire contains 8 "Yes/No" questions and the number of "Yes" answers provide a total score (range 0-8).
Patients that answer "Yes" to 3-4 questions are typically considered to be at intermediate risk of OSA.
|
30 days
|
Patient Reported Outcome Measurement Information System (PROMIS)
Time Frame: 30 days
|
Patient Reported Outcome Measurement Information System is a 10 item questionnaire that measures physical, mental, and social health in adults.
It can be used on the general population and patients with chronic conditions.
Patients rate their health based on a severity scale of 1-5 (1 indicates poor health) and the scoring system allows each question/item to be evaluated separately.
|
30 days
|
Chronic Obstructive Pulmonary Disease Assessment Tool (CAT)
Time Frame: 30 days
|
Chronic Obstructive Pulmonary Disease (COPD) Assessment Tool is a questionnaire that measures the impact the disease has on patients well being and daily life.
There are 8 questions that ask about common symptoms COPD patients experience and the patient indicates their severity (range 0-5).
A total of the scores are added (range 0-40) and scores of at least 30 indicate that their COPD has a very high level of impact on their daily lives.
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dennis Hwang, MD, Kaiser Permanente, Fontana Medical Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KPSleep-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Continuous Positive Airway Pressure
-
University Hospital, GrenobleResMed; Société francophone de pneumologie de langue francaiseCompletedType 1 Diabetes | Sleep Apnea SyndromeFrance
-
University Hospital, MontpellierCompletedCoronary Artery Disease | Sleep Apnea SyndromeFrance
-
Sanjay R PatelBeth Israel Deaconess Medical Center; National Institutes of Health (NIH); Brigham...CompletedSleep Apnea, Obstructive | Diabetes MellitusUnited States
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina
-
Fisher and Paykel HealthcareHelios Klinik AmbrockCompleted
-
Poitiers University HospitalCompletedObstructive Sleep Apnea Syndromes
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Hospital, MontpellierUnknownObstructive Sleep Apnea Syndrome | Brain InfarctionFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedSleep Apnea, Obstructive | Fatigue | SarcoidosisItaly
-
Eileen R. ChasensCompletedSleep Apnea, Obstructive | Diabetes Mellitus, Type 2United States